Crown Bioscience April 2023 Newsletter
Crown Bioscience
We support drug discovery through translational research across oncology and immuno-oncology.
Welcome to the monthly Crown Bioscience newsletter. Discover some of our April highlights below to keep up to date with our recent developments, and to learn more about our services. Don't forget to follow us on LinkedIn to avoid missing our daily updates!
We were delighted to present some of our most recent scientific data at the AACR23 Annual Meeting and to showcase new and exciting in vitro, in vivo and ex vivo oncology and immuno-oncology platforms and services.
All of our AACR23 scientific posters are now accessible, outlining innovative preclinical and translational research solutions.
If you did not attend AACR23, you can still schedule a meeting with us to discuss how our solutions can be tailored to your preclinical and translational study needs!
We celebrated World Organoid Research Day with a series of interviews with our esteemed scientists, who shared their knowledge on how organoid research is revolutionizing our understanding and management of various diseases. To learn more about organoid research, watch the recording of our webinar by Dr. Rajendra Kumari, a leading expert in the field!
Screen your compound across well validated panels of in vivo models. Choose from our panel of 6 or 12 Syngeneic, or 6 Tumor Homograft models to accelerate your drug development. Upcoming registration deadlines include:
• May 9, Tumor Homograft - 6 Model
• May 19, Syngeneic - 6 Model
Recommended by LinkedIn
Proteomics analysis on xenografts is more challenging than expected, because of the nature of the mixture of human cancer cells and mouse somatic cells in the same tissue. We are excited to share our latest publication in Cancer Research Communications, which highlights a major breakthrough in the field of proteomic analysis for xenografts.
Did you know we offer the most comprehensive catalog of well-characterized in vivo autoimmune and inflammatory disease models ? These recapitulate key clinical and pathological features of human disease, forming an integrated platform for preclinical drug development? Learn more about our in vivo models for IBD, diabetes, rheumatoid arthritis, and many more!
For our April spotlight, we’re highlighting pretreated head and neck cancer PDX model HN2574. View the patient treatment history, SOC data, pathology images, and other details about this model in our free PDX database , HuBase™
Our acquisition of Indivumed’s Service business and supporting biobank is complete! We are delighted to announce that the new entity, now known as Indivumed Services, has become a wholly owned subsidiary of Crown Bioscience and includes all associated laboratory operations in Hamburg, Germany and Frederick, MD, US.
© 2023 Crown Bioscience, Inc.
Crown Bioscience, Inc. 16550 West Bernardo Drive, Building 5, Suite 525, San Diego, CA 92127, United States